<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230564</url>
  </required_header>
  <id_info>
    <org_study_id>B1371038</org_study_id>
    <nct_id>NCT04230564</nct_id>
  </id_info>
  <brief_title>Acute Myeloid Leukemia Real World Treatment Patterns</brief_title>
  <official_title>Characteristics, Treatment Patterns, and Clinical Outcomes in Non-intensive Chemotherapy Acute Myeloid Leukemia (AML) Patients - a US Real-World Study Using Electronic Medical Record Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      Among patients with a diagnosis of AML who received non-intensive chemotherapy:

        -  Describe patient demographic and clinical characteristics

        -  Describe treatment patterns

        -  Describe effectiveness outcomes

        -  Evaluate tumor response
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>January 1, 2012 to January 10, 2020</time_frame>
    <description>Overall survival was the duration from diagnosis of disease to death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>January 1, 2012 to January 10, 2020</time_frame>
    <description>Time from the treatment initiation date to the date of treatment failure (TF), relapse from CR or better, or death from any cause, whichever comes first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse Free Survival</measure>
    <time_frame>January 1, 2012 to January 10, 2020</time_frame>
    <description>Time from the treatment initiation date to the date of a relapse event, or death from any cause, whichever comes first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best response</measure>
    <time_frame>January 1, 2012 to January 10, 2020</time_frame>
    <description>Best response recorded from treatment start until disease progression/recurrence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to best response</measure>
    <time_frame>January 1, 2012 to January 10, 2020</time_frame>
    <description>Time from treatment initiation until best response recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of best response</measure>
    <time_frame>January 1, 2012 to January 10, 2020</time_frame>
    <description>Time from best response achieved until lose of response or the end of the record, whichever occurs first</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>AML</arm_group_label>
    <description>Patients diagnosed with AML</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>Patients taking azacitidine</description>
    <arm_group_label>AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venetoclax</intervention_name>
    <description>patients taking venetoclax</description>
    <arm_group_label>AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glasdegib</intervention_name>
    <description>patients taking glasdegib</description>
    <arm_group_label>AML</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include adult patients diagnosed with AML who, at any point during first
        line therapy, received non-intensive therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must meet all of the following inclusion criteria to be eligible for inclusion in
        the study:

          1. Confirmed diagnosis of AML on or after 01 January 2012 through Clinical Research Nurse
             (CRN) review of provider documentation of AML diagnosis in the medical record.

          2. Receipt of non-intensive therapy at any point during first line therapy following
             initial AML diagnosis. For this study, non-intensive therapy will be defined as 1 of
             the following agents, alone or in combination with any other agent:

               1. AZA

               2. GLAS

               3. VEN

          3. Age â‰¥18 years at initial diagnosis of AML.

        Exclusion Criteria:

        Patients meeting any of the following criteria will not be included in the study:

        1. Record of 1 or more of the following confounding diagnoses at any point before or after
        AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive
        systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia;
        dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Concerto HealthAI</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia (AML)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

